Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe

Table 3 Inflammatory markers at baseline and 12 weeks after randomization

	Rosuvastatin 10 mg/day (n = 24)	Rosuvastatin 2.5 mg/day + ezetimibe 10 mg/day (n = 22)
hs-CRP (mg/L)
Baseline	2.0 ± 2.0	2.5 ± 2.5
12 weeks	1.4 ± 2.1*	1.3 ± 1.1*
12 weeks - baseline	−1.0 ± 2.5	−1.3 ± 1.9
MDA-LDL (U/L)
Baseline	104.6 ± 26.8	94.2 ± 18.8
12 weeks	99.7 ± 26.3	91.3 ± 22.8
12 weeks - baseline	−2.7 ± 23.3	−3.9 ± 21.5
IL-6 (pg/mL)
Baseline	3.1 (2.4 – 4.5)	3.5 (2.5 - 5.0)
12 weeks	2.8 (2.3 – 4.6)	3.2 (2.1 - 4.7)
12 weeks - baseline	0.2 (−0.7 - 0.8)	−0.4 (−1.3 - 0.4)
TNF-α (pg/mL)
Baseline	1.8 (1.2 - 2.1)	1.9 (1.3 - 7.0)
12 weeks	1.8 (1.2 - 2.5)	1.7 (1.4 - 3.8)
12 weeks - baseline	0.3 (−0.2 - 0.8)	−0.2 (−2.8 - 0.5)
PTX3 (ng/mL)
Baseline	1.55 (1.21 - 2.32)	1.82 (1.47 - 2.24)
12 weeks	1.65 (1.22 - 2.67)	1.76 (1.49 - 2.50)
12 weeks - baseline	0.12 (−0.09 - 0.98)	0.01 (−0.30 - 0.51)

Data are shows as means ± standard deviation. hs-CRP, high sensitivity-C-reactive protein; IL-6, interleukin-6; MDA-LDL, malondialdehyde-modified-low-density lipoprotein; PTX3, pentraxin 3; TNF-α, tumour necrosis factor-α. *p < 0.05 vs. baseline.

ISSN: 1476-511X